Glaxo Joins J&J in $200 Million Fund With Index Ventures

GlaxoSmithKline Plc and Johnson & Johnson are forming a $200 million fund with Index Ventures to invest in early-stage biotechnology companies, a move that may entice venture capitalists back to the industry.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.